hPSCreg®
This website uses cookies to keep track of login sessions and for internal Matomo Statistics. See our Privacy Policy for details. This website uses cookies, learn more


UKAi001-B-1

Registration Summary:

hsc3_hiPS_29_23, IRF8-/- iPS2

UKAi001-B-1

General

Cell Line
hPSCreg name UKAi001-B-1
Cite as:
UKAi001-B-1 (RRID:CVCL_A5GR)
Alternative name(s)
hsc3_hiPS_29_23, IRF8-/- iPS2
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UKAi001-A-1
(hsc3_hiPS_11_4, IRF8-/- iPS1)
Donor's gene variants:
KRAS, KRAS
Donor diseases:
systemic mastocytosis
UKAi001-C-1
(hsc3_hiPS_40_16_6, IRF8-/- iPS3)
Donor's gene variants:
KRAS, KRAS
Donor diseases:
systemic mastocytosis
UKAi001-B
(iPS2, hsc3_hiPS_29)
Donor's gene variants:
KRAS, KRAS
Donor diseases:
systemic mastocytosis
UKAi001-A
(iPS1, hsc3_hiPS_11)
Donor's gene variants:
KRAS, KRAS
Donor diseases:
systemic mastocytosis
UKAi001-C
(hsc3_hiPS_40, iPS3)
Donor's gene variants:
KRAS, KRAS
Donor diseases:
systemic mastocytosis
UKAi004-B
(patient 1 control 2, P4_wt8)
Donor's gene variants:
KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53
Donor diseases:
systemic mastocytosis
UKAi004-A
(P4_wt4, patient 1 control 1)
Donor's gene variants:
KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53
Donor diseases:
systemic mastocytosis
UKAi004-C
(P4_mut13, patient 1 D816V 1)
Donor's gene variants:
KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53
Donor diseases:
systemic mastocytosis
UKAi004-D
(P4_mut28, patient 1 D816V 2)
Donor's gene variants:
KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53
Donor diseases:
systemic mastocytosis
UKAi004-E
(P4_mut30, patient 1 D816V 3)
Donor's gene variants:
KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53
Donor diseases:
systemic mastocytosis
UKAi007-A
(P13_wt5, Patient 2 control 1)
Donor's gene variants:
PDGFRA, PDGFRA, RUNX1, RUNX1, RUNX1, RUNX1, KIT, KIT, ABL1, ABL1, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1, IDH1, IDH1, SRSF2, SRSF2
Donor diseases:
systemic mastocytosis
UKAi007-B
(P13_mut1, Patient 2 D816V 1)
Donor's gene variants:
PDGFRA, PDGFRA, RUNX1, RUNX1, RUNX1, RUNX1, KIT, KIT, ABL1, ABL1, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1, IDH1, IDH1, SRSF2, SRSF2
Donor diseases:
systemic mastocytosis
UKAi008-A
(Patient 3 control 1, P15_wt37)
Donor's gene variants:
PDGFRA, PDGFRA, KIT, KIT, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1
Donor diseases:
systemic mastocytosis
UKAi008-B
(Patient 3 control 2, P15_wt108)
Donor's gene variants:
PDGFRA, PDGFRA, KIT, KIT, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1
Donor diseases:
systemic mastocytosis
UKAi008-C
(Patient 3 D816V 1, P15_mut131)
Donor's gene variants:
PDGFRA, PDGFRA, KIT, KIT, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1
Donor diseases:
systemic mastocytosis
Last update 12th February 2021
Notes Sontag et al., Stem Cells 35, 898-908, 2017. PMID:28090699
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider
Generator Universitätsklinikum Aachen (UKA)
Owner Universitätsklinikum Aachen (UKA)
Distributors
Derivation country Germany

External Databases
BioSamples SAMEA8192627
Cellosaurus CVCL_A5GR
Wikidata Q107117208

General Information
Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information
Sex male

Phenotype and Disease related information (Donor)
Diseases A disease was diagnosed.
Systemic mastocytosis
mast cell leukemia (DOID:9254)
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMCD - systemic mast cell disease
  • systemic tissue mast cell disease
Genetic variants
KRAS (target)
12p12.1
KRAS G436A
Heterozygous
VCV000197243.1
PMID:28090699
KRAS G436A mutation (NM_033360.4) is a disease-associated mutation and not a disease-causing mutation. Samples were from a mastocytosis patient but the iPS cell clones did not contain the disease-causing mutation KIT D816V but rather a heterozygous KRAS G436A mutation, which we refer to as disease associated mutation.

Karyotyping (Donor)
Has the donor karyotype been analysed?
No

Other Genotyping (Donor)
Is there genome-wide genotyping or functional data available?
No

Donor Relations
Other cell lines of this donor

External Databases (Donor)
BioSamples SAMEA8133083

Ethics

Also have a look at the ethics information for the parental line UKAi001-B .
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Life Technologies
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General
The source cell information can be found in the parental cell line UKAi001-B.

Reprogramming method
Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
Unknown

Vector free reprogramming

Other
Selection criteria for clones Human ES cell-like morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells mouse embryonic fibroblasts
Passage method Enzymatically
Collagenase
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: Knock out DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
bFGF 10 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
POU5F1 (OCT-4)
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
human albumin
Yes
alpha fetoprotein
Yes
FOXA2
Yes
SOX 17
Yes
Hematopoietic Precursor Cell
Ont Id: CL_0008001
In vitro spontaneous differentiation
In vitro directed differentiation
Marker Expressed
cardiac troponin T
Yes
CD34
Yes
CD43
Yes
CD45
Yes
PECAM1
Yes
ckit
Yes
MHC6
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
NES
Yes
beta III tubulin
Yes
Sox1
Yes
PAX6
Yes

Microbiology / Virus Screening
HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?
Yes
46 XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease
IRF8 (target)
Gene knock-out
IRF8 deletions were determined by Sanger Sequencing (Sontag et al., 2017, Supporting Information Figure 2A and B).
CRISPR-associated (CRISPR/Cas) System